91. Budd-Chiari syndrome Clinical trials / Disease details
Clinical trials : 4 / Drugs : 5 - (DrugBank : 4) / Drug target genes : 4 - Drug target pathways : 14
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2100046725 | 2022-01-01 | 2021-05-27 | The efficacy and safety of Warfarin and Rivaroxaban to prevent re-occlusion for Budd-Chiari syndrome with membranous obstruction after percutanouse balloon angioplasty | To compare the efficacy and safety of Warfarin and Rivaroxaban to prevent re-occlusion for Budd-Chiari syndrome with membranous obstruction after percutanouse balloon angioplasty | Budd-Chiari syndrome | Warfarin group:oral take Warfarin;Rivaroxaban group:oral take rivaroxaban; | The First Affiliated Hospital of Zhengzhou University | NULL | Recruiting | 18 | 75 | Both | Warfarin group:40;Rivaroxaban group:40; | N/A | China |